Biochem Biophys Res Commun
December 2024
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a member of the genus Betacoronavirus (subgenus Sarbecovirus) and shares significant genomic and phylogenetic similarities with severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1). SARS-CoV-2 infection occurs through membrane fusion between the virus and host cell membranes, which is facilitated by the spike glycoprotein subunit 2 (S2). The folding of three heptad-repeat regions 1 (HR1) into a central trimeric core structure, along with the binding of three heptad-repeat regions 2 (HR2) in an antiparallel manner within the groove formed between the HR1 regions, which provides the driving force for membrane fusion.
View Article and Find Full Text PDFSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for COVID-19, has caused an ongoing worldwide pandemic. Due to the rapid emergence of variants of concern (VOCs), novel vaccines and vaccination strategies are urgently needed. We developed an intranasal vaccine consisting of the SARS-CoV-2 receptor binding domain (RBD) fused to the antibody Fc fragment (RBD-Fc).
View Article and Find Full Text PDFThe development of covalent organic framework nanosheet (COF NS) is becoming a vitally important research field by reason of its high permeability, ordered structure, high utilization of functional site, favourable dispersability and large aspect ratio, resulting in their widespread applications in separation, catalysis, sensing and optical device. In this work, a Tp-Bpy COF NS was prepared via an interfacial synthesis of 2,4,6-triformylphloroglucinol (Tp) and 5,5'-diamino-2,2'-bipyridine (Bpy), which has film morphology, high surface area, large pore, excellent stability and various functional site. It was utilized as a functional material to immobilize aptamers for constructing a sensitive electrochemical aptasensor.
View Article and Find Full Text PDFBackground: Asthma patients potentially have impaired adaptive immunity to virus infection. The levels of SARS-CoV-2-specific adaptive immunity between COVID-19 survivors with and without asthma are presently unclear.
Methods: COVID-19 survivors (patients with asthma n=11, with allergies n=8, and COVID-19 only n=17) and non-COVID-19 individuals (asthmatic patients n=10 and healthy controls n=9) were included.